Elkhorn Partners Limited Partnership Purchases Shares of 600 GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Elkhorn Partners Limited Partnership acquired a new position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 600 shares of the company’s stock, valued at approximately $47,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. CoreFirst Bank & Trust purchased a new stake in GE HealthCare Technologies in the fourth quarter valued at about $25,000. Runnymede Capital Advisors Inc. acquired a new position in shares of GE HealthCare Technologies during the fourth quarter valued at about $28,000. Bank of Jackson Hole Trust purchased a new position in shares of GE HealthCare Technologies in the 4th quarter valued at approximately $32,000. OFI Invest Asset Management acquired a new stake in GE HealthCare Technologies in the 4th quarter worth approximately $34,000. Finally, Flagship Wealth Advisors LLC purchased a new stake in GE HealthCare Technologies during the 4th quarter worth approximately $34,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on GEHC shares. Wells Fargo & Company lifted their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. The Goldman Sachs Group raised GE HealthCare Technologies from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $85.00 to $100.00 in a research report on Tuesday, March 11th. Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their price objective for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. Finally, Citigroup lifted their target price on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, GE HealthCare Technologies presently has an average rating of “Moderate Buy” and a consensus target price of $97.73.

GE HealthCare Technologies Stock Up 0.9 %

GEHC opened at $62.81 on Monday. The company has a fifty day moving average of $81.75 and a two-hundred day moving average of $84.00. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04. GE HealthCare Technologies Inc. has a fifty-two week low of $57.65 and a fifty-two week high of $94.80. The stock has a market capitalization of $28.72 billion, a price-to-earnings ratio of 14.51, a PEG ratio of 3.19 and a beta of 1.14.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The company had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $5.33 billion. On average, research analysts expect that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.

GE HealthCare Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Friday, April 25th will be issued a $0.035 dividend. This represents a $0.14 annualized dividend and a yield of 0.22%. The ex-dividend date is Friday, April 25th. GE HealthCare Technologies’s payout ratio is presently 3.23%.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.